AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-K$HBIO

HARVARD BIOSCIENCE INC (HBIO): Investor presentation

HARVARD BIOSCIENCE INC (HBIO) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 NASDAQ: HBIO Harvard Bioscience Investor Overview November 202 6 Forward - Looking Statements This document contains forward - looking statements within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995 . Forwa

Original reporting
SEC EDGAR 8-K
Published Nov 10, 2026, 12:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 12:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$HBIO
Neutral
medium confidence
Mentioned
$HBIO
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$HBIONeutralMed
01

Why it matters

The disclosed guidance may lead to a modest re‑rating of the stock by analysts and a small price move.

02

Market read

The filing provides the first public view of FY26 expectations, offering a modest trading edge for investors tracking micro‑caps.

03

What to watch

Execution risk of the manufacturing consolidation and the success of new product innovations could materially affect outcomes.

Relevance 6/10Novelty 6/10Timing: today

Background

Harvard Bioscience used its SEC 8‑K filing to outline forward‑looking financial targets, cost‑saving projects, and leadership changes.

Company-level read

Ticker impact

$HBIONeutralMedium confidence
Context

Harvard Bioscience filed an 8‑K presenting FY2025 revenue of $87 M and FY26 growth guidance of 3‑5% YoY, plus cost‑saving projects.

Expected impact

likely modest upside as investors price in the updated growth outlook

Evidence & confidence

Guidance is higher than prior expectations but the absolute numbers are small for a micro‑cap; market reaction is expected to be limited.

Market effects

Sector

May reinforce optimism for the translational science tools niche, but impact on broader life‑sciences sector is limited.

Regional

Primarily U.S. micro‑cap investors; no significant regional effect.

Global

Low global relevance beyond niche biotech investors.

Counterpoint

What could challenge this read

The guidance could be seen as overly optimistic given macro‑economic headwinds, suggesting a potential overvaluation.

Key entities

  • company
    Harvard Bioscience Inc.

    Life‑sciences tools manufacturer listed on Nasdaq.

Read at source← All news

Related articles

Med

Harvard Bioscience, Inc. Q3 2026 Earnings Call Summary

Harvard Bioscience reported Q3 2026 revenue growth of 8%, driven by CRO demand and new product innovations. China revenue rose 31% year-over-year. Gross margins were pressured by lower-margin products. Full-year revenue guidance was reaffirmed at 3-5% growth, but adjusted EBITDA guidance was lowered. Project Viking is expected to deliver cost savings in 2027. Management expects to launch a bioproduction version of electroporation technology in mid-2027.

finance.yahoo.com
$HBIOHigh

Harvard Bioscience (HBIO) Q3 2026 Earnings Call Transcript

Harvard Bioscience (HBIO) reported Q3 2026 revenue of $22.2M, up 8% YoY, driven by CRO and distribution partner demand. Adjusted EBITDA was $1.8M, impacted by lower-margin products. The company reaffirmed full-year revenue guidance of 3-5% growth and adjusted gross margin target of 57-59%. Project Viking, a manufacturing consolidation plan, is on track for 2027 completion, expected to generate $3M in cost savings.

finance.yahoo.com
$HBIOMed

Harvard Bioscience Announces Third Quarter 2026 Financial Results

HARVARD BIOSCIENCE INC (HBIO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Harvard Bioscience Announces Third Quarter 2026 Financial Results · Third Quarter 2026 Revenue Growth of 8% Year Over Year to $22.2 Million · Reaffirms Full Year 2026 Revenue Guidance of 3%-5% Year Over Year Growth HOLLISTON, Mass., November 10, 2026 (GLOBE NEWSWIRE)

SEC EDGAR 8-K
$HBIOMedAI 8/10

Harvard Bioscience (HBIO) Q2 2026 Earnings Call Transcript

Harvard Bioscience (HBIO) reported Q2 2026 revenue of $22.7M, up 11%, and adjusted EBITDA of $1.7M, up 11%. Full-year revenue guidance was raised to 3-5% growth, but gross margin guidance was lowered to 57-59% due to product and geographic mix shifts. The company expects $3M in cost savings from Project Viking in 2027. Americas and APAC regions showed strong growth, while Europe grew modestly. Adjusted EPS was -$0.14, and Q3 revenue guidance is $21.0M-$22.6M.

fool.com
$HBIOMed

Harvard Bioscience, Inc. Q2 2026 Earnings Call Summary

Harvard Bioscience (HBIO) reported Q2 2026 revenue up 11%, driven by CRO demand and double-digit growth in telemetry and CMT portfolios. China sales rose on its “Made in China” BTX line. Recurring revenue reached 55%. Full-year guidance raised to 3% to 5% growth, but adjusted gross margin cut 100 bps to 57% to 59%, with Project Viking cost savings.

yahoo.com